Table 2.
Whole sample |
Cases |
Controls |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Study | n | β | s.e. | P | β | s.e. | P | β | s.e. | P |
Radiant | 3251 | 0.08 | 0.02 | 0.001 | 0.12 | 0.03 | 6.2 × 10−5 | −0.04 | 0.04 | 0.3 |
PsyCoLaus | 2994 | 0.07 | 0.02 | 0.006 | 0.12 | 0.04 | 8.5 × 10−4 | 0.03 | 0.03 | 0.44 |
GSK | 1677 | 0.04 | 0.03 | 0.193 | 0.01 | 0.05 | 0.89 | 0.09 | 0.04 | 0.04 |
MARS | 1116 | 0.06 | 0.04 | 0.119 | 0.08 | 0.06 | 0.16 | 0.04 | 0.05 | 0.45 |
NESDA/NTR | 4663 | 0.09 | 0.02 | 1.2 × 10−5 | 0.2 | 0.04 | 2.3 × 10−8 | 0.01 | 0.02 | 0.56 |
Meta-analysis: fixed effects | 13 701 | 0.07 | 0.01 | 1.3 × 10−12 | 0.12 | 0.02 | 6.9 × 10−11 | 0.02 | 0.01 | 0.15 |
BMI, body mass index; GSK, GlaxoSmithKline study; MARS, Munich Antidepressant Response Signature project; NESDA/NTR, Netherlands Study of Depression and Anxiety/Netherlands Twin Register.